Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-il 17 and anti-il 23 monoclonal antibodies: a retrospective observational study

Background The aim of this study is to confront the effectiveness of anti-IL 17 versus anti-IL 23 mAb in treating palmoplantar psoriasis by comparing the incidence of patients that required a therapy switch to another mAb class. Furthermore, we calculated the mean time intercurrent the beginning therapy with mAbs and the necessity to switch class due to ineffectiveness.